Consistent with canonical MYC-driven gene expression, well-defined MYC targets such as TERT, the catalytic component of telomerase (64), JAG2, a receptor on the NOTCH signalling pathway (65), TRAP1, a key mitochondrial chaperone (66), and FABP5, linked to fatty acid metabolism and a potential therapeutic vulnerability in myeloma (67), were increased (Fig 2E). The gene discussed is JAG2; the disease is plasma cell myeloma.